Current treatment options have improved survival rates but have not provided a cure. Eventually, initial therapies stop ...

At 38, author Jonathan Gluck was diagnosed with blood cancer and given less than three years to live. He's written a memoir ...

Multiple myeloma is considered incurable, but a third of patients in a clinical trial have lived without detectable cancer for years, after facing certain death ...

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple ...

ChristianaCare’s Helen F. Graham Cancer Center & Research Institute is the first in Delaware to offer a powerful new tool in ...

In the front row, Dr. Bruno Paiva, with the team from the Multiple Myeloma Group at Cima and the Clínica Universidad de ...

ISB 2001, a first-in-class trispecific antibody developed by IGI, showed a 79% response rate in relapsed/refractory multiple ...

In the two decades since a young father was diagnosed with multiple myeloma, clinical trials and advances in treating his ...

CellCentric has secured a Series C raise of $120million to advance its drug inobrodib, a first-in-class oral cancer drug to ...

Ichnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), ...